Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENPAD
2024-518122-33-00Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of clopidogrel in arteriosclerosis obliterans (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Adverse clinical events related to arterial thrombosis at 24 months. Started Dec 2024; status: completed.
02
Drugs
clopidogrel
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-518122-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518122-33-00.